Komori
Other Disclosures4582SymBio Pharmaceuticals LimitedPharmaceuticals

Brincidofovir (BCV): Pre-submission Consultation with the UK's MHRA Confirmed

The date for a pre-submission consultation with the UK's MHRA regarding the application for approval of brincidofovir (BCV) in the UK was confirmed as 3 December 2026. Formal submission of the marketing authorization application is scheduled for the end of January 2027.

Worth reading
65In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Improvement
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Conditional
How definitive the wording is.

Announced details

Brincidofovir (BCV) / SyB V-1901 injection
Applicable field (uses covered by this announcement)

Adenovirus infections after hematopoietic stem cell transplantation (UK)

Launch date3 December 2026 (scheduled date of pre-submission consultation) / End of January 2027 (scheduled submission of formal application)
What the company reported numerically
Usage history

45 registered patients in the global Phase III clinical trial as of the end of October 2026

Relationship between the counterparty and the company
SymBio Pharmaceuticals Limited4582
Relationship with the Company

The company will hold a pre-submission consultation in connection with the application for marketing authorization of BCV in the UK. シンバイオ製薬 obtained a global license for BCV in September 2019.

CounterpartyMedicines and Healthcare products Regulatory Agency (MHRA)

An agency under the UK's Department of Health and Social Care. It is the executive agency responsible for the authorisation and safety of medicines and medical devices.

Impact on Business Performance

No impact on the consolidated earnings outlook for the fiscal year ending December 2026

The company does not address Contract Value / Offering price.

Source (materials cited by the company)

IDWeek 2024 (Infectious Diseases Society of America conference) and the press release dated 23 October 2024

Announced details
ItemDetails
Names of Products / Services CoveredBrincidofovir (BCV) / SyB V-1901 injection
CounterpartyMedicines and Healthcare products Regulatory Agency (MHRA)
Counterparty overviewAn agency under the UK's Department of Health and Social Care. It is the executive agency responsible for the authorisation and safety of medicines and medical devices.
Relationship with the CompanyThe company will hold a pre-submission consultation in connection with the application for marketing authorization of BCV in the UK. シンバイオ製薬 obtained a global license for BCV in September 2019.
Launch date3 December 2026 (scheduled date of pre-submission consultation) / End of January 2027 (scheduled submission of formal application)
Applicable areaAdenovirus infections after hematopoietic stem cell transplantation (UK)
Usage history45 registered patients in the global Phase III clinical trial as of the end of October 2026
Impact on Business PerformanceNo impact on the consolidated earnings outlook for the fiscal year ending December 2026
SourceIDWeek 2024 (Infectious Diseases Society of America conference) and the press release dated 23 October 2024
Items this document does not state (9)
Contract ValueOffering priceContract DateAward/certification nameAwarding / certifying bodyRegistration number and expiry dateLocationLocation scaleQuantitative Effects

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

In preparation for the marketing authorization application scheduled for January 2027, the company will incorporate advice and views from the MHRA into the application documents, enhance the application and improve the prospects of obtaining approval.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Brincidofovir (BCV): Pre-submission Consultation with the UK's MHRA Confirmed | SymBio Pharmaceuticals Limited (4582) timely disclosure | Komori